{
  "id": "mhgap#risk_safety_986ef3bd",
  "content": "References\n154. Siefried KJ, Acheson LS, Lintzeris N, Ezard N. 162. Sancho M, De Gracia M, Rodríguez RC, Mallorquí-\nPharmacological treatment of methamphetamine/ Bagué N, Sánchez-González J, Trujols J et al.\namphetamine dependence: a systematic review. Mindfulness-based interventions for the treatment\nCNS Drugs. 2020;34(4):337–65 (https://doi. of substance and behavioral addictions: a\norg/10.1007/s40263-020-00711-x). systematic review. Front Psychiatry. 2018;9:95\n(https://doi.org/10.3389/fpsyt.2018.00095).\n155. Naji L, Dennis B, Rosic T, Wiercioch W, Paul J,\nWorster A et al. Mirtazapine for the treatment 163. Beraldo L, Gil F, Ventriglio A, de Andrade AG, da\nof amphetamine and methamphetamine use Silva AG, Torales J et al. Spirituality, religiosity\ndisorder: a systematic review and meta-analysis. and addiction recovery: current perspectives. Curr\nDrug Alcohol Depend. 2022;232:109295 (https:// Drug Res Rev. 2019;11(1):26–32 (https://doi.org/10\ndoi.org/10.1016/j.drugalcdep.2022.109295). .2174/1874473711666180612075954).\n156. Lam L, Anand S, Li X, Tse ML, Zhao JX, Chan EW. 164. Walton-Moss B, Ray EM, Woodruff K. Relationship\nEfficacy and safety of naltrexone for amfetamine of spirituality or religion to recovery from\nand methamfetamine use disorder: a systematic substance abuse: a systematic review. J Addict\nreview of randomized controlled trials. Clin Nurs. 2013;24(4):217–8 (https://doi.org/10.1097/\nToxicol. 2019;57(4):225–33 (https://doi.org/10.1080 JAN.0000000000000001).\n/15563650.2018.1529317).\n165. Vest N, Reinstra M, Timko C, Kelly J, Humphreys\n157. Minozzi S, Saulle R, De Crescenzo F, Amato L. K. College programming for students in addiction",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "relationships",
      "coping_skill",
      "risk_safety",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety References\n154. Siefried KJ, Acheson LS, Lintzeris N, Ezard N. 162. Sancho M, De Gracia M, Rodríguez RC, Mallorquí-\nPharmacological treatment of methamphetamine/ Bagué N, Sánchez-González J, Trujols J et al.\namphetamine dependence: a systematic review. Mindfulness-based interventions for the treatment\nCNS Drugs. 2020;34(4):337–65 (https://doi. of substance and behavioral addictions: a\norg/10.1007/s40263-020-00711-x). systematic review. Front Psychiatry. 2018;9:95\n(https://doi.org/10.3389/fpsyt.2018.00095).\n155. Naji L, Dennis B, Rosic T, Wiercioch W, Paul J,\nWorster A et al. Mirtazapine for the treatment 163. Beraldo L, Gil F, Ventriglio A, de Andrade AG, da\nof amphetamine and methamphetamine use Silva AG, Torales J et al. Spirituality, religiosity\ndisorder: a systematic review and meta-analysis. and addiction recovery: current perspectives. Curr\nDrug Alcohol Depend. 2022;232:109295 (https:// Drug Res Rev. 2019;11(1):26–32 (https://doi.org/10\ndoi.org/10.1016/j.drugalcdep.2022.109295). .2174/1874473711666180612075954).\n156. Lam L, Anand S, Li X, Tse ML, Zhao JX, Chan EW. 164. Walton-Moss B, Ray EM, Woodruff K. Relationship\nEfficacy and safety of naltrexone for amfetamine of spirituality or religion to recovery from\nand methamfetamine use disorder: a systematic substance abuse: a systematic review. J Addict\nreview of randomized controlled trials. Clin Nurs. 2013;24(4):217–8 (https://doi.org/10.1097/\nToxicol. 2019;57(4):225–33 (https://doi.org/10.1080 JAN.0000000000000001).\n/15563650.2018.1529317).\n165. Vest N, Reinstra M, Timko C, Kelly J, Humphreys\n157. Minozzi S, Saulle R, De Crescenzo F, Amato L. K. College programming for students in addiction References\n154. siefried kj, acheson ls, lintzeris n, ezard n."
}